December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcus Biosciences, Inc. Common Stock (NY:RCUS)

30.48 -0.28 (-0.91%)
Streaming Delayed Price Updated: 10:00 AM EDT, Aug 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcus Biosciences, Inc. Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences, Inc.
Via Business Wire
News headline image
Arcus Biosciences Provides Update on Clinical Programs, Including Key 2022 Milestones
From Arcus Biosciences, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers Oncternal Therapeutics (NASDAQ:ONCT 
Via Benzinga
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-Stage Programs and New Research Collaboration
From Arcus Biosciences, Inc.
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences, Inc.
Via Business Wire
News headline image
Why Arcus Biosciences Stock Vaulted Higher in November ↗
Arcus was one of the few winners in the turbulent biotech space last month. 
Via The Motley Fool
News headline image
Taiho Pharmaceutical Exercises Option for an Exclusive License to Arcus Biosciences’ Anti-TIGIT Program in Japan and Certain Territories in Asia
From Arcus Biosciences, Inc.
Via Business Wire
News headline image
Arcus Biosciences to Participate in the Upcoming Evercore ISI HealthCONx 2021 Conference
From Arcus Biosciences, Inc.
Via Business Wire
News headline image
54 Biggest Movers From Yesterday ↗
Gainers Longeveron Inc. (NASDAQ: LGVN) shares climbed 135.3% to close at $6.87 on Thursday. Longeveron said the FDA granted rare pediatric disease designation for the company... 
Via Benzinga
News headline image
Arcus Stock Rockets To Record As Gilead Unexpectedly Opts Into Cancer Drugs ↗
Gilead opted into three programs from a small biotech company, sending shares flying. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers Dicerna Pharmaceuticals (NASDAQ:DRNA) shares moved upwards by 78.87% to $38.06 during Thursday's regular session. As of 12:30 EST, this security is trading at... 
Via Benzinga
News headline image
44 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Longeveron Inc. (NASDAQ: LGVN) jumped 157% to $7.51. Longeveron said the FDA granted rare pediatric disease designation for the company’s Lomecel-B for the... 
Via Benzinga
News headline image
Why Are Arcus Biosciences Shares Trading Higher Today? ↗
Gilead Sciences Inc (NASDAQ: GILD) has exercised its options to three programs in Arcus Biosciences Inc (NYSE: RCUS) portfolio, including both anti-TIGIT... 
Via Benzinga
News headline image
Why Arcus Biosciences Stock Is On Fire Today ↗
Gilead Sciences has decided to exercise its options for three of the biotech's oncology programs. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Gainers Dicerna Pharmaceuticals (NASDAQ:DRNA) stock increased by 78.28% to $37.94 during Thursday's pre-market session. The market value of their outstanding shares is... 
Via Benzinga
News headline image
Gilead Exercises Options to Three Arcus Biosciences Clinical-Stage Programs and Adds Research Collaboration
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences, Inc.
Via Business Wire
News headline image
Recap: Arcus Biosciences Q3 Earnings ↗
Arcus Biosciences (NYSE:RCUS) reported its Q3 earnings results on Monday, November 8, 2021 at 04:10 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
News headline image
Arcus Biosciences Reports Third Quarter 2021 Financial Results and Provides an Update on our anti-TIGIT Domvanalimab
From Arcus Biosciences, Inc.
Via Business Wire
News headline image
Arcus Biosciences to Report Third Quarter 2021 Financial Results & Recent Corporate Highlights
From Arcus Biosciences, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 8, 2021 ↗
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •... 
Via Benzinga
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences, Inc.
Via Business Wire
News headline image
Arcus Biosciences to Participate at Upcoming Investor Conferences
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences, Inc.
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences, Inc.
Via Business Wire
News headline image
Arcus Biosciences Reports Second Quarter 2021 Financial Results and Provides Operational Highlights
From Arcus Biosciences, Inc.
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.